Research interview


Videointervju med Cantargias vd Göran Forsberg

to view this content. Not a member?
Why should I sign up?
We’ll help you find the best stocks. With an account you gain access to all the research and information needed to improve your stock performance.
No commitment required
A few perks of having an account:
Full access to our research
Full access to our livestreams and video content
Customized research feed based on your preferences
If you have any other questions, don’t hesitate to contact us at or +46 (0)8 545 013 30

Cantargias vd Göran Forsberg berättar om den senaste prekliniska datan som presenteras på American Association for Cancer Research (AACR), status i CAN04 samt arbetet om att flytta upp till Nasdaqs huvudlista. Redeyes analytiker Mathias Spinnars intervjuar.